Back to School 2020
Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview
Genmab CEO van de Winkel believes data sharing, more basket trials will be central to accelerating drug development, now and after COVID-19
Genmab CEO Jan van de Winkel believes data sharing and more basket trials will be central to accelerating drug development, now and after COVID-19.
Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive networks.
Van de Winkel, president and CEO of Genmab A/S (CSE:GMAB; NASDAQ:GMAB), spoke to BioCentury as part of the Back to School 2020 series of audio interviews with key industry leaders (see Cover Story: “The Imperative of COVID-19”).
Van de Winkel thinks the networking spirit spawned during the pandemic should carry over to other sectors, in particular digital sciences, where data sciences can help accelerate drug development. “The biggest progress in the future,” he said, “will be made at interfaces between different industries, and